Company Overview and News

to your dashboard

Headline News

OPKO Health: A House Of Cards Tumbling In The Dark

2017-11-17 seekingalpha
A slew of undisclosed or thinly disclosed executive team departures in the diagnostics division, which represents over 82.8% of revenue, could signal business decline and a compliance “house-cleaning”. (73-0)

Cramer's lightning round: Opko Health is a 'neighborhood of pain'

2017-11-16 cnbc
Opko Health Inc.: "Oh my god, the quarter, not good. I mean, this thing has become a genuine house of pain. No, this is like a neighborhood of pain. And until [CEO] Dr. Frost comes on, we're going to back away. We have to. We have to." (207-1)

What Do Versartis (NASDAQ: VSAR)'s Troubles Mean For Opko Health (NASDAQ: OPK)? | Benzinga

2017-11-16 benzinga
Versartis Inc (NASDAQ: VSAR) shares are slumping even as rival Opko Health Inc. (NASDAQ: OPK) is seeing slight strength, though not proportionate to the sell-off seen in Versartis shares. (144-2)

General Electric, Synergy Pharma Stuck Again in Tuesday’s 52-Week Low Club

2017-11-14 247wallst
November 14, 2017: Here are four stocks trading with heavy volume among 170 equities making new 52-week lows in Tuesday’s session. On the NYSE decliners led advancers by about 3 to 2 and on the Nasdaq, decliners and advancers by less than 4 to 3. (333-3)

The Interesting Company That Produces An Anti-Aging Pill

2017-11-14 seekingalpha
ChromaDex has a product that can has multiple health benefits, including resistance to weight gain, improved control of blood sugar and cholesterol, reduced nerve damage, and longer lifespan. (79-0)

Billionaires Club Investing In ChromaDex As Revenue Grows

2017-11-10 seekingalpha
Recent change in company strategy includes sale of their lab business and more focus on Niagen (NR) sales. (147-1)

OPKO Health (OPK) Posts Wider-Than-Estimated Loss in Q3

2017-11-10 zacks
OPKO Health, Inc. (OPK - Free Report) reported loss of 8 cents per share in the third quarter of 2017, compared with a loss of 3 cents a year ago. Moreover, the loss was wider than the Zacks Consensus Estimate of a loss of 5 cents. (83-0)

OPKO Health's (OPK) CEO Phillip Frost on Q3 2017 Results - Earnings Call Transcript

2017-11-09 seekingalpha
Welcome to the OPKO Health Third Quarter Business Update Conference Call. At this time, all participants are in a listen-only mode. Following management’s prepared remarks, we’ll hold a Q&A session. [Operator Instructions] As a reminder, this conference is being recorded November 8, 2017. (75-1)

4 Medical Device Stocks to Top Q3 Earnings

2017-11-01 zacks
We are in the thick of the earnings season with more than 64.2% of the index’s total market capitalization having already released their quarterly numbers. Meanwhile, in the MedTech space, uncertainty related to the Trump administration’s Obamacare repeal & replacement effort continues to make headlines. The latest uproar is related to the President’s newly-released executive order, designed to provide affordable quality healthcare to the nation. (104-2)

Insight From The Stellar Scientist Trader - An Integrated BioSci Investing Report

2017-10-25 seekingalpha
In the previous week, Dr. Tran BioSci of Integrated BioSci Investing had the honor to sit down with the expert, Decision Analytics in an interview. Our readers greatly benefited from his wisdom. His recommendation on Spectrum Pharmaceuticals (NASDAQ:SPPI) proved correct. The stock increased 36% the following day (and reached its 52-weeks high) after the accurate forecasting of the phase 2 trial (which studied poziotinib as a treatment for non small cell lung cancer with exon 20 mutation). (372-5)

OPKO Health (OPK) Signs New Agreement with Japan Tobacco

2017-10-13 zacks
Diversified healthcare company, OPKO Health Inc. (OPK - Free Report) recently signed an exclusive agreement with Japan Tobacco Inc for the development and commercialization of its kidney drug, RAYALDEE. Japan Tobacco will be responsible for all regulatory approvals and commercial activities pertaining to RAYALDEE in Japan.   (153-0)

Opko Health Inks $118 Million Deal with Japan Tobacco, Inc. for Rayaldee

2017-10-12 biospace
MIAMI, Oct. 12, 2017 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) announced that its subsidiary EirGen Pharma has entered into an exclusive agreement with Japan Tobacco Inc. (JT) for the development and commercialization in Japan of RAYALDEE® for the treatment of secondary hyperparathyroidism (SHPT) in non-dialysis and dialysis patients with chronic kidney disease (CKD). (75-0)

A Lost Year For OPKO Health

2017-10-12 seekingalpha
The expectations cycle for the company was negative over the last 9-12 months but could soon change for the better. (73-1)

BRIEF-Opko Health enters into exclusive agreement with Japan Tobacco to develop and commercialize Rayaldee in Japan

2017-10-12 reuters
* Opko Health enters into exclusive agreement with Japan Tobacco to develop and commercialize Rayaldee® in Japan (75-0)

Stock Research Report

Opko Health is a diversified healthcare company that seeks to establish industry-leading positions in large and rapidly growing medical markets. Its diagnostics business includes BioReference Laboratories (“BioReference”), the nation’s third-largest clinical laboratory with a core genetic testing business and a 400-person sales and marketing team to drive growth and leverage new products, including the 4Kscore prostate cancer test and the Claros 1 in-office immunoassay platform (in development). Opko Health's pharmaceutical business features Rayaldee , an FDA-approved treatment for secondary hyperparathyroidism (“SHPT”) in adults with stage 3 or 4 chronic kidney disease (“CKD”) and vitamin D insufficiency (launched in November 2016), and VARUBI™ for chemotherapy-induced nausea and vomiting (oral formulation launched by partner TESARO in November 2015 and pending approval for IV formulation), OPK88003, a once or twice weekly oxyntomodulin for type 2 diabetes and obesity which is a clini...

Click for full article
CUSIP: 68375N903